ATP5MFP6

Across TCGA pan-cancer cohorts, ATP5MFP6 RNA is linked to patient survival in 12 of 34 cancer types, making it the most broadly survival-associated ATP5MFP6 data layer.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher ATP5MFP6 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated ATP5MFP6 expression acts as an unfavorable survival marker, although some lineages such as PRAD and ESCA show a favorable association.

STAD, SKCM, and COAD are the cancer types where ATP5MFP6 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	DFS	Tertile	II,III,IV	0.355	0.630	.003	59	view →
SKCM	DFS	Tertile	All	0.571	0.748	.008	39	view →
COAD	OS	Tertile	II,III,IV	0.233	0.574	.008	27	view →
THCA	OS	Tertile	III,IV	0.870	0.987	.001	21	view →
TGCT	DFS	Tertile	II,III,IV	0.088	0.917	.010	18	view →
LIHC	OS	Tertile	All	0.610	0.783	.030	18	view →
KIRC	DFS	Median	All	0.716	0.841	.007	14	view →
LAML	DFS	Median	All	0.433	0.697	.004	14	view →
PRAD	DFS	Tertile	All	0.973	0.759	.040	12	view →
PAAD	OS	Tertile	II,III,IV	0.331	0.572	.003	9	view →
BLCA	DFS	Tertile	III,IV	0.078	0.489	<.001	9	view →
ESCA	DFS	Median	All	0.912	0.555	.031	1	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 12 lineages.

ATP5MFP6–STAD (DFS)

Open the STAD breakdown →